NEW YORK (TheStreet) - With so many well-managed biotech names out there like Medtronic (MDT) and Stryker (SYK), making a strong argument for shares of Amgen (AMGN) has always been difficult, given the uncertainties that surround the company's pipeline.
Although Amgen's cancer drug Neulasta has been a huge success, analysts have done nothing but complain that Teva Pharmaceuticals (TEVA), which is working on a rival product will eventually eat up 25% of Amgen's quarterly revenue. And to say nothing about the threat that exists from biosimilars like Roche (RHHBY) and AbbVie (ABBV), which deal in Amgen's territory of generic biologic compounds.
But here's the thing; these and other concerns have been around for the past 12 to 18 months. Yet, during that span, shares of Amgen, which have climbed almost 90%, have soared on the wave of excitement generated by these same Pharma and biotech rivals that have worried the Street with potential attacks.
Essentially, these worries about Amgen's lack of competitive position have had the opposite effect. And following Amgen's $125-per-share acquisition of Onyx Pharmaceuticals (ONXX), which should help Amgen narrow its growth gap over the next three years, the Street has no choice but to value Amgen closer to its peers, given the advantage that it now has in its sales and manufacturing infrastructure.
In that regard, given the company's better-than-expected third-quarter earnings results, which sent shares soaring to a record high, the sky's now the limit for this company. Revenue was up 10% year over year to $4.75 billion, which beat analyst expectations of $4.58 billion. While it's true that a government order worth $155 million was a key contributor in the quarter, I was nonetheless impressed by the balance shown in Amgen's portfolio of products.